Ismail R K, Schramel F M N H, van Dartel M, Hilarius D L, de Boer A, Wouters M W J M, Smit H J M
Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands.
Department of Pulmonary Diseases, St Antonius Hospital, Utrecht, Nieuwegein, the Netherlands.
Lung Cancer. 2020 Nov;149:68-77. doi: 10.1016/j.lungcan.2020.08.011. Epub 2020 Aug 21.
This study describes the initiation of the Dutch Lung Cancer Audit for Lung Oncology (DLCA-L) and reports the first results of three years of clinical auditing.
The initiation, dataset, and data quality of the DLCA-L are described. For the analyses, all patients registered from 2017 to 2019 were included. Descriptive statistics were used to assess the first outcomes of the DLCA-L, including results from quality indicators, patient- and tumor characteristics, and the real-world use of immunotherapy.
The DLCA-L was initiated after the surgery and radiotherapy audit for lung cancer. In total, 33.788 NSCLC patients and 4.293 SCLC patients were registered in the DLCA-L from 2017 to 2019. Seventy-three (97 %) Dutch hospitals participated in the DLCA-L in 2019. The registry became nation-wide in 2020. The data quality improved over the years, with complete cases in 90 % of the NSCLC patients. In total, 15 quality indicators were established based on DLCA-L data to improve processes and clinical outcomes. An example of these quality indicators was brain imaging at diagnosis of stage III NSCLC patients, which increased from 80 % in 2017 to 90 % in 2019 and hospital variation was reduced. The DLCA-L provided data on immunotherapy use in stage IV NSCLC (n = 4.415) patients. These patients had a median age of 67 years and 11 % of the patients had an ECOG PS ≥ 2. The number of patients treated with immunotherapy in different hospitals varied between 2 patients to 163 patients per hospital.
The DLCA-L has become a valuable and complete data source with national coverage in 2020. A high number of registered patients and limited missing data resulted in better insights into hospital processes and outcomes of lung cancer care. Quality indicators were, with success, used to establish improvements and minimize hospital variation. The DLCA-L also provides hospitals real-world information on the use of (systemic) therapies.
本研究描述了荷兰肺癌肿瘤学审计(DLCA-L)的启动情况,并报告了三年临床审计的首批结果。
描述了DLCA-L的启动、数据集和数据质量。分析纳入了2017年至2019年登记的所有患者。使用描述性统计来评估DLCA-L的首批结果,包括质量指标结果、患者和肿瘤特征以及免疫疗法的实际应用情况。
DLCA-L是在肺癌手术和放疗审计之后启动的。2017年至2019年,DLCA-L共登记了33788例非小细胞肺癌(NSCLC)患者和4293例小细胞肺癌(SCLC)患者。2019年,73家(97%)荷兰医院参与了DLCA-L。该登记系统于2020年覆盖全国。多年来数据质量有所提高,90%的NSCLC患者数据完整。基于DLCA-L数据共建立了15项质量指标,以改进流程和临床结果。这些质量指标的一个例子是III期NSCLC患者诊断时的脑部成像,从2017年的80%增加到2019年的90%,且医院间差异减小。DLCA-L提供了IV期NSCLC(n = 4415)患者免疫疗法使用的数据。这些患者的中位年龄为67岁,11%的患者东部肿瘤协作组(ECOG)体能状态(PS)≥2。不同医院接受免疫疗法治疗的患者数量在每家医院2例至163例之间。
DLCA-L已成为2020年具有全国覆盖范围的宝贵且完整的数据源。大量登记患者和有限的缺失数据有助于更好地了解医院肺癌护理流程和结果。质量指标成功用于改进并减少医院间差异。DLCA-L还为医院提供了(全身)疗法使用的真实世界信息。